635712-59-3 Usage
Uses
Used in Pharmaceutical Industry:
(R)-2-benzyloxycarbonylamino-3-[2-methyl-3-(2-trimethylsilanyl-ethanesulfonyl)-3H-benzoimidazol-5-yl]-propionic acid methyl ester is used as a building block for the synthesis of novel pharmaceutical compounds. Its structural complexity and the presence of various functional groups allow for the creation of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-2-benzyloxycarbonylamino-3-[2-methyl-3-(2-trimethylsilanyl-ethanesulfonyl)-3H-benzoimidazol-5-yl]-propionic acid methyl ester serves as a valuable research tool. Its unique structure and functional groups can be further modified and investigated to understand their effects on biological targets, potentially leading to the development of new therapeutic agents.
Used in Drug Design:
(R)-2-benzyloxycarbonylamino-3-[2-methyl-3-(2-trimethylsilanyl-ethanesulfonyl)-3H-benzoimidazol-5-yl]-propionic acid methyl ester is used as a starting point for designing new drugs. Its structural features can be optimized to enhance interactions with specific biological targets, potentially improving the efficacy and selectivity of the resulting drug candidates.
Used in Drug Development:
This complex organic compound is also utilized in the development of new drugs. Its structural and functional properties can be leveraged to create molecules with improved pharmacokinetic and pharmacodynamic profiles, which may lead to more effective and safer therapeutic options for various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 635712-59-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,5,7,1 and 2 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 635712-59:
(8*6)+(7*3)+(6*5)+(5*7)+(4*1)+(3*2)+(2*5)+(1*9)=163
163 % 10 = 3
So 635712-59-3 is a valid CAS Registry Number.
635712-59-3Relevant academic research and scientific papers
CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS
-
Page 135-136, (2010/02/04)
The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
